Blog Read the latest perspectives from our team of subject matter experts and others From Fragmented to Connected: Unlocking the Power of 360° HCP EngagementAt Fierce Pharma Week 2025, Stacey Rivkin took the stage to address one of pharma’s most persistent challenges: despite having more data than ever before, medical and commercial teams still… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology KOL EngagementFrom Fragmented to Connected: Unlocking the Power of 360° HCP EngagementAt Fierce Pharma Week 2025, Stacey Rivkin took the stage to address one of pharma’s most persistent challenges: despite having more data than ever before, medical and commercial teams still… Continue reading → Read the articleyes KOL EngagementHow H1 Integrates with Your CRM of ChoiceAt H1, we know that every life sciences organization has unique needs when it comes to customer relationship management (CRM). Some companies rely on long-established platforms, while others are adopting… Continue reading → Read the articleno Drug DevelopmentBridging the Feasibility Gap: A Smarter Path to Clinical Trial EnrollmentDespite decades of progress in data access and analytics, the clinical research industry continues to struggle with one seemingly simple challenge: enrolling patients on time. The statistics are stark: nearly… Continue reading → Read the articleno Drug DevelopmentWhy More Data Hasn’t Improved Clinical Trial EnrollmentIn clinical trial feasibility, we face a counterintuitive reality: despite unprecedented access to healthcare professional data, identifying the right investigators and predicting enrollment success has become increasingly challenging. This… Continue reading → Read the articleno Provider DataCEO Insights: Solving Healthcare’s Provider Data Challenge Through H1’s Acquisition of VedaToday, I’m proud to announce that H1 is acquiring Veda. This follows our acquisition of Ribbon Health in December 2024. By bringing in Veda’s suite of products, data, team, and… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationHow Incyte Is Advancing Clinical Trial RepresentationClinical trial representation is more than just a regulatory requirement—it’s a critical component of accessible healthcare. Ensuring that trial participants reflect the real-world patient population leads to more effective… Continue reading → Read the articleno1234›»
